Alejandro Romero MartÃ-nez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/231113/publications.pdf

Version: 2024-02-01

110 papers	3,624 citations	94433 37 h-index	149698 56 g-index
118 all docs	118 docs citations	118 times ranked	5509 citing authors

#	Article	IF	Citations
1	Permethrin-induced oxidative stress and toxicity and metabolism. A review. Environmental Research, 2016, 149, 86-104.	7.5	180
2	A review of metalâ€catalyzed molecular damage: protection by melatonin. Journal of Pineal Research, 2014, 56, 343-370.	7.4	145
3	Novel tacrine-related drugs as potential candidates for the treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1916-1922.	2.2	134
4	DonepezilÂ+ÂpropargylamineÂ+Â8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2014, 80, 543-561.	5.5	128
5	Influence of the extraction method on the recovery of bioactive phenolic compounds from food industry by-products. Food Chemistry, 2022, 378, 131918.	8.2	103
6	A History of the Pharmacological Treatment of Bipolar Disorder. International Journal of Molecular Sciences, 2018, 19, 2143.	4.1	101
7	Guanosine protects human neuroblastoma SH-SY5Y cells against mitochondrial oxidative stress by inducing heme oxigenase-1 via PI3K/Akt/GSK-3Î² pathway. Neurochemistry International, 2012, 61, 397-404.	3.8	98
8	Neuroprotective effect of melatonin against ischemia is partially mediated by alphaâ€7 nicotinic receptor modulation and <scp>HO</scp>â€1 overexpression. Journal of Pineal Research, 2014, 56, 204-212.	7.4	93
9	The Antioxidant Additive Approach for Alzheimerâ€™s Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators. Journal of Medicinal Chemistry, 2016, 59, 9967-9973.	6.4	83
10	MultitargetâEDirected Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H₃R Antagonism for Neurodegenerative Diseases. Angewandte Chemie - International Edition, 2017, 56, 12765-12769.	13.8	83
11	New Melatoninâ€“N,N-Dibenzyl(N-methyl)amine Hybrids: Potent Neurogenic Agents with Antioxidant, Cholinergic, and Neuroprotective Properties as Innovative Drugs for Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2014, 57, 3773-3785.	6.4	81
12	Mycotoxins modify the barrier function of Caco-2 cells through differential gene expression of specific claudin isoforms: Protective effect of illite mineral clay. Toxicology, 2016, 353-354, 21-33.	4.2	80
13	Ischemic brain injury: New insights on the protective role of melatonin. Free Radical Biology and Medicine, 2017, 104, 32-53.	2.9	80
14	Poststress treatment with PNU282987 can rescue SH-SY5Y cells undergoing apoptosis via Î±7 nicotinic receptors linked to a Jak2/Akt/HO-1 signaling pathway. Free Radical Biology and Medicine, 2010, 49, 1815-1821.	2.9	75
15	Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives. Journal of Medicinal Chemistry, 2010, 53, 5129-5143.	6.4	69
16	Neuroprotective effect of guanosine against glutamateâ€induced cell death in rat hippocampal slices is mediated by the phosphatidylinositolâ€3 kinase/Akt/ glycogen synthase kinase 3Î² pathway activation and inducible nitric oxide synthase inhibition. Journal of Neuroscience Research, 2011, 89, 1400-1408.	2.9	69
17	Cadmium exposure differentially modifies the circadian patterns of norepinephrine at the median eminence and plasma LH, FSH and testosterone levels. Toxicology Letters, 2004, 146, 175-182.	0.8	68
18	Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2012, 54, 750-763.	5.5	66

#	Article	IF	Citations
19	Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells. Journal of Pineal Research, 2010, 49, 141-148.	7.4	65
20	Cytotoxicity induced by deltamethrin and its metabolites in SH-SY5Y cells can be differentially prevented by selected antioxidants. Toxicology in Vitro, 2012, 26, 823-830.	2.4	63
21	Novel Tacrineâ€Grafted Ugi Adducts as Multipotent Antiâ€Alzheimer Drugs: A Synthetic Renewal in Tacrineâ€“Ferulic Acid Hybrids. ChemMedChem, 2015, 10, 523-539.	3.2	62
22	Fipronil sulfone induced higher cytotoxicity than fipronil in SH-SY5Y cells: Protection by antioxidants. Toxicology Letters, 2016, 252, 42-49.	0.8	62
23	ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy. Frontiers in Neuroscience, 2016, 10, 294.	2.8	58
24	Synthesis and pharmacological assessment of diversely substituted pyrazolo[3,4-b]quinoline, and benzo[b]pyrazolo[4,3-g][1,8]naphthyridine derivatives. European Journal of Medicinal Chemistry, 2011, 46, 4676-4681.	5.5	52
25	Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles. Bioorganic and Medicinal Chemistry, 2010, 18, 5861-5872.	3.0	48
26	Galantamine elicits neuroprotection by inhibiting iNOS, NADPH oxidase and ROS in hippocampal slices stressed with anoxia/reoxygenation. Neuropharmacology, 2012, 62, 1082-1090.	4.1	48
27	Effect of cadmium on 24-h variations in hypothalamic dopamine and serotonin metabolism in adult male rats. Experimental Brain Research, 2003, 149, 200-206.	1.5	47
28	N-Acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2011, 46, 2224-2235.	5.5	46
29	New cinnamic â€“ N-benzylpiperidine and cinnamic â€“ N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties. European Journal of Medicinal Chemistry, 2016, 121, 376-386.	5.5	46
30	The emergence of melatonin in oncology: Focus on colorectal cancer. Medicinal Research Reviews, 2019, 39, 2239-2285.	10.5	46
31	Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles. Bioorganic and Medicinal Chemistry, 2011, 19, 122-133.	3.0	44
32	Neurotoxicity Induced by Okadaic Acid in the Human Neuroblastoma SH-SY5Y Line Can Be Differentially Prevented by Î±7 and Î²2* Nicotinic Stimulation. Toxicological Sciences, 2011, 123, 193-205.	3.1	44
33	Toxicological and pharmacological evaluation, antioxidant, ADMET and molecular modeling of selected racemic chromenotacrines {11-amino-12-aryl-8,9,10,12-tetrahydro-7H-chromeno[2,3-b]quinolin-3-ols} for the potential prevention and treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2014, 74, 491-501.	5.5	44
34	Oxidative stress and gene expression profiling of cell death pathways in alpha-cypermethrin-treated SH-SY5Y cells. Archives of Toxicology, 2017, 91, 2151-2164.	4.2	42
35	Toxic effects of cadmium on the regulatory mechanism of dopamine and serotonin on prolactin secretion in adult male rats. Toxicology Letters, 2005, 155, 87-96.	0.8	40
36	Relationship between blood concentrations of heavy metals and cytogenetic and endocrine parameters among subjects involved in cleaning coastal areas affected by the â€˜Prestigeâ€™ tanker oil spill. Chemosphere, 2008, 71, 447-455.	8.2	40

#	Article	IF	Citations
37	Protective effect of creatine against 6-hydroxydopamine-induced cell death in human neuroblastoma SH-SY5Y cells: Involvement of intracellular signaling pathways. Neuroscience, 2013, 238, 185-194.	2.3	38
38	Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease. European Journal of Medicinal Chemistry, 2018, 156, 534-553.	5.5	38
39	Evidence for dose-additive effects of a type II pyrethroid mixture. In vitro assessment. Environmental Research, 2015, 138, 58-66.	7.5	35
40	Melatonin as potential candidate to prevent the toxicity induced by chemical warfare agents. Archives of Toxicology, 2014, 88, 3-4.	4.2	34
41	Nontoxic and Neuroprotective Î²-Naphthotacrines for Alzheimerâ€™s Disease. Chemical Research in Toxicology, 2013, 26, 986-992.	3.3	33
42	Melatonin protects against oxygen and glucose deprivation by decreasing extracellular glutamate and Nox-derived ROS in rat hippocampal slices. NeuroToxicology, 2016, 57, 61-68.	3.0	33
43	Both Creatine and Its Product Phosphocreatine Reduce Oxidative Stress and Afford Neuroprotection in an In Vitro Parkinsonâ€™s Model. ASN Neuro, 2014, 6, 175909141455494.	2.7	32
44	Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding. Hepatology, 2012, 56, 706-714.	7.3	30
45	Effect of cadmium on lymphocyte subsets distribution in thymus and spleen. Journal of Physiology and Biochemistry, 2003, 59, 43-48.	3.0	29
46	Effects of in utero and lactational exposure to endosulfan in prefrontal cortex of male rats. Toxicology Letters, 2008, 176, 58-67.	0.8	29
47	Calcium signalling mediated through Î±7 and nonâ€Î±7 nAChR stimulation is differentially regulated in bovine chromaffin cells to induce catecholamine release. British Journal of Pharmacology, 2011, 162, 94-110.	5.4	27
48	New flavonoid â€“ N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for AlzheimerÂ´s disease endowed with neurogenic properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 712-727.	5.2	27
49	Melatonin Reduces NLRP3 Inflammasome Activation by Increasing Î±7 nAChR-Mediated Autophagic Flux. Antioxidants, 2020, 9, 1299.	5.1	26
50	Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in inÂvitro and inÂvivo models related to brain ischemia. Neuropharmacology, 2013, 67, 403-411.	4.1	25
51	Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?. Cellular and Molecular Neurobiology, 2022, 42, 489-500.	3.3	25
52	Neurotoxicity induced by dexamethasone in the human neuroblastoma SH-SY5Y cell line can be prevented by folic acid. Neuroscience, 2011, 190, 346-353.	2.3	23
53	Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration. Future Medicinal Chemistry, 2017, 9, 765-780.	2.3	21
54	The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease. Journal of Psychiatry and Neuroscience, 2017, 42, 59-69.	2.4	21

#	Article	IF	Citations
55	Potential of Melatonin as Adjuvant Therapy of Oral Cancer in the Era of Epigenomics. Cancers, 2019, 11, 1712.	3.7	21
56	PP2A Ligand ITH12246 Protects against Memory Impairment and Focal Cerebral Ischemia in Mice. ACS Chemical Neuroscience, 2013, 4, 1267-1277.	3.5	20
57	Differential induction of cytochrome P450 isoforms and peroxisomal proliferation by cyfluthrin in male Wistar rats. Toxicology Letters, 2013, 220, 135-142.	0.8	20
58	Modulation of serine/threonine phosphatases by melatonin: therapeutic approaches in neurodegenerative diseases. British Journal of Pharmacology, 2018, 175, 3220-3229.	5.4	20
59	Wnt Signaling Pathway, a Potential Target for Alzheimer's Disease Treatment, is Activated by a Novel Multitarget Compound <scp>ASS</scp>234. CNS Neuroscience and Therapeutics, 2014, 20, 568-570.	3.9	19
60	The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy. Antioxidants, 2021, 10, 1152.	5.1	19
61	Modulatory Effects of Melatonin on Cadmium-Induced Changes in Biogenic Amines in Rat Hypothalamus. Neurotoxicity Research, 2011, 20, 240-249.	2.7	18
62	Synthesis and biological evaluation of heterocyclic privileged medicinal structures containing (benz)imidazole unit. Monatshefte FÃ¼r Chemie, 2016, 147, 2209-2220.	1.8	16
63	Modulation of Heat Shock Response Proteins by ASS234, Targeted for Neurodegenerative Diseases Therapy. Chemical Research in Toxicology, 2018, 31, 839-842.	3.3	16
64	Dibenzo[1,4,5]thiadiazepine: A hardly-known heterocyclic system with neuroprotective properties of potential usefulness in the treatment of neurodegenerative diseases. European Journal of Medicinal Chemistry, 2014, 81, 350-358.	5.5	15
65	Neuroprotective effects of Eâ€PodoFavalinâ€15999 (AtremorineÂ®). CNS Neuroscience and Therapeutics, 2017, 23, 450-452.	3.9	15
66	Melatonin's efficacy in stroke patients; a matter of dose? A systematic review. Toxicology and Applied Pharmacology, 2020, 392, 114933.	2.8	15
67	Neuroinflammation Signaling Modulated by ASS234, a Multitarget Small Molecule for Alzheimerâ€™s Disease Therapy. ACS Chemical Neuroscience, 2018, 9, 2880-2885.	3.5	14
68	Effect of nitric oxide on prolactin secretion and hypothalamic biogenic amine contents. Life Sciences, 2004, 74, 1681-1690.	4.3	13
69	Toxic effects of cadmium on GABA and taurine content in different brain areas of adult male rats. Journal of Physiology and Biochemistry, 2005, 61, 439-446.	3.0	13
70	Recent Developments on Multi-Target-Directed Tacrines for Alzheimer's Disease. I. The Pyranotacrines. Current Topics in Medicinal Chemistry, 2018, 17, 3328-3335.	2.1	13
71	Toxicity induced by chemical warfare agents: Insights on the protective role of melatonin. Chemico-Biological Interactions, 2013, 206, 134-142.	4.0	12
72	ITH12410/SC058: A New Neuroprotective Compound with Potential in the Treatment of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2014, 5, 770-775.	3.5	12

#	Article	IF	Citations
73	QuinoxalineTacrine QT78, a Cholinesterase Inhibitor as a Potential Ligand for Alzheimerâ€™s Disease Therapy. Molecules, 2019, 24, 1503.	3.8	12
74	Development of HuperTacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimerâ€™s Disease. Mini-Reviews in Medicinal Chemistry, 2015, 15, 648-658.	2.4	12
75	Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer's disease. Future Medicinal Chemistry, 2014, 6, 1883-1891.	2.3	11
76	Upregulation of Antioxidant Enzymes by <scp>ASS</scp>234, a Multitarget Directed Propargylamine for Alzheimer's Disease Therapy. CNS Neuroscience and Therapeutics, 2016, 22, 799-802.	3.9	11
77	Effect of natamycin on cytochrome P450 enzymes in rats. Food and Chemical Toxicology, 2013, 62, 281-284.	3.6	10
78	Neuroprotective effect of dimebon against ischemic neuronal damage. Neuroscience, 2014, 267, 11-21.	2.3	10
79	5-Methyl-N-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5H-indolo[2,3-b]quinolin-11-amine: a highly potent human cholinesterase inhibitor. MedChemComm, 2017, 8, 1307-1317.	3.4	10
80	Highlights of ASS234: a novel and promising therapeutic agent for Alzheimerâ€™s disease therapy. Neural Regeneration Research, 2020, 15, 30.	3.0	10
81	Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout. Journal of Medicinal Chemistry, 2022, 65, 6250-6260.	6.4	10
82	Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?. Diseases (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382 T	2.5	9
83	Melatonin and Nitrones As Potential Therapeutic Agents for Stroke. Frontiers in Aging Neuroscience, 2016, 8, 281.	3.4	7
84	In Vitro and In Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases. ACS Chemical Neuroscience, 2020, 11, 3793-3801.	3.5	7
85	Understanding the oncostatic actions displayed by melatonin in colorectal cancer therapy. Future Medicinal Chemistry, 2020, 12, 1201-1204.	2.3	6
86	Role of serendipity in the discovery of classical antidepressant drugs: Applying operational criteria and patterns of discovery. World Journal of Psychiatry, 2022, 12, 588-602.	2.7	5
87	Enantioselective Neuroprotective Effects of Tacripyrine <scp>ITH</scp>122 Against Oxygen and Glucose Deprivation in Rat Hippocampal Slices. CNS Neuroscience and Therapeutics, 2013, 19, 285-287.	3.9	4
88	Multitarget-Directed Antioxidants as Therapeutic Agents. , 2017, , 5-46.		4
89	Analysis of gene expression profiles of CR80, a neuroprotective 1,8-Naphthyridine. Future Medicinal Chemistry, 2018, 10, 1289-1300.	2.3	4
90	Detection of Neurological and Ophthalmological Pathologies with Optical Coherence Tomography Using Retinal Thickness Measurements: A Bibliometric Study. Applied Sciences (Switzerland), 2020, 10, 5477.	2.5	4

#	Article	IF	Citations
91	Melatonin and neurodegeneration: From neurotoxic environment to cell resilience. Advances in Molecular Toxicology, 2020, 13, 69-108.	0.4	4
92	Melatonin: A hypothesis for Kawasaki disease treatment. Medical Hypotheses, 2018, 119, 6-10.	1.5	3
93	The crossroads of melatonin: Bibliometric analysis and mapping of global scientific research. Melatonin Research, 2021, 4, 152-172.	1.1	3
94	Multipotente Liganden mit kombinierter Cholinesteraseâ€•und Monoaminooxidaseâ€Inhibition sowie Histaminâ€H 3 Râ€Antagonismus bei neurodegenerativen Erkrankungen. Angewandte Chemie, 2017, 129, 12939-12943.	2.0	2
95	In silico assessment of the metabolism and its safety significance of multitarget propargylamine <scp>ASS</scp>234. CNS Neuroscience and Therapeutics, 2018, 24, 981-983.	3.9	2
96	Chemical weapons of mass destruction and terrorism: a threat analysis. , 2020, , 79-94.		2
97	In Silico Prediction of the Toxic Potential of Neuroprotective Bifunctional Molecules Based on Chiral N-Propargyl-1,2-amino Alcohol Derivatives. Chemical Research in Toxicology, 2021, 34, 1245-1249.	3.3	2
98	Impact of melatonin effects on toxicology of vesicant chemical warfare agents: When science meets reality. Melatonin Research, 2020, 3, 101-119.	1.1	2
99	Alkylating Agent-Induced Toxicity and Melatonin-Based Therapies. Frontiers in Pharmacology, 2022, 13, 873197.	3.5	2
100	In vitro assessment of adsorbents to prevent disruption of the intestinal barrier by mycotoxins. Toxicology Letters, 2013, 221, S149.	0.8	1
101	The food contaminants aflatoxin B1, fumonisin B1, ocratoxina, T-2 toxin and deoxynivalenol decrease intestinal barrier permeability in human Caco-2 cells. Protector role of clay additives. Toxicology Letters, 2014, 229, S170.	0.8	0
102	In vitro relative potency of Type II pyrethroids and mixture dose-effects on oxidative stress cytotoxicity in SH-SY5Y, HepG2 and Caco-2 human cell lines. Toxicology Letters, 2014, 229, S45.	0.8	0
103	Melatonin as a Novel Therapeutic Agent Against Chemical Warfare Agents. , 2016, , 177-191.		0
104	Therapeutic Potential of Melatonin in Combination with Other Drugs Against Neurodegeneration. , 2016, , 91-99.		0
105	BENEFITS OF SELF-LEARNING BEFORE THE LECTURES. INTED Proceedings, 2018, , .	0.0	0
106	RECREATING REAL CASES WITH VIRTUAL TOOLS IN RISK ASSESSMENT. , 2018, , .		0
107	LEARNING TOXICOLOGY ON LINE. INTED Proceedings, 2019, , .	0.0	0
108	ACQUIREMENT OF THEORETICAL KNOWLEDGE WITH PRACTICAL TOXICOLOGY. , 2020, , .		0

#	Article	IF	Citations
109	A SELF-LEARNING TOXICOLOGY EXPERIENCE. , 2020, , .		0
110	IMPLEMENTING CONTINUOUS ASSESSMENT IN TOXICOLOGY. INTED Proceedings, 2022, , .	0.0	0